Respiratory Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

Striverdi Respimat Inhaler Approved

The FDA has approved Striverdi Respimat (olodaterol; Boehringer Ingelheim) 5mcg inhalation spray for the treatment of COPD.

COPD Costs: $49 Billion by 2020

Medical costs for COPD in the United States are more than $32 billion each year.

Obesity in Pregnancy, Offspring Asthma

Maternal obesity in pregnancy and high maternal gestational weight gain are associated with an elevated risk of childhood asthma.

Asthma Meds Could Stunt Growth

For children with persistent asthma, use of inhaled corticosteroids (ICS) is associated with a significant reduction in linear growth velocity.

Pediatric TB Rates Higher Than Expected

The incidence of pediatric tuberculosis is higher than the number of infections in 22 high-burden countries.

Sleep-Disordered Breathing & Pregnancy

Sleep-disordered breathing (SDB) may be associated with adverse pregnancy outcomes,including gestational diabetes.

Asthma Treatments: Inhalations

Review this updated chart on inhalations for asthma treatment for quick information when you need it.

New Drug Product: Breo Ellipta

Long term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.

News

New Once-Daily Inhaler for Asthma Approved

GlaxoSmithKline announced that the Food and Drug Administration (FDA) has approved Arnuity Ellipta (fluticasone furoate inhalation powder) for the maintenance treatment of asthma as prophylactic therapy in patients ≥12 years old.

Hospitalization Less Likely With Artificially Altered Oximetry in Bronchiolitis Infants

Among infants presenting to an emergency department with mild to moderate bronchiolitis, hospitalization is less likely for those with an artificially elevated pulse oximetry reading.

Sleep Apnea, Resistant Elevated Blood Pressure Linked Despite Antihypertensive Tx

There is a strong association between severe untreated obstructive sleep apnea (OSA) and resistant elevated blood pressure (BP), despite treatment with an aggressive antihypertensive medication regimen.

Featured courses from mycme

Pharmacology Workshop: New Drugs, Obesity, Arthritis (Pharmacology Credit)External web site

This activity provides in-depth guidance for the pharmacologic and nonpharmacologic treatment of arthritis, and management ...

CE 3.00 Credits

COPD: Current Medical Therapy (Pharmacology Credit)External web site

This activity will explain different ways to treat patients suffering from COPD using medications and ...

CE 1.00 Credits

Sign Up for Free e-newsletters